Creatine, the supplement that has been fueling gym selfies and questionable lifting form for decades, may have a new gig: helping the immune system take on cancer. A study from UCLA, published in iScience, suggests that creatine can boost dendritic cells - the immune system's scouts that spot tumors and rally the killer T cells to attack. The research, conducted in mice and human cells, builds on earlier work from the same lab showing creatine also perks up cancer-fighting T cells directly.

Immunotherapy, the modern marvel that rallies the body's own defenses against cancer, works wonders for about 20% to 40% of patients - which is great if you're in that club, but leaves a lot of people stuck with the 'sorry, not for you' speech. The UCLA team thinks that by energizing dendritic cells, which are basically the generals directing T cell troops, creatine could make immunotherapy work for more people. 'Immunotherapy has shown remarkable promise, but it only works for a subset of patients,' said Lili Yang, the study's senior author. 'What this study shows is that creatine doesn't just help the T cells fighting cancer - it also energizes the entire infrastructure that supports and guides them.'

So how does creatine do this? The researchers looked at metabolic genes in dendritic cells that had infiltrated mouse tumors and found that the gene for the creatine transporter - the protein that hauls creatine into cells - was way more active in those tumor-infiltrating cells than in dendritic cells from healthy tissue. When they engineered dendritic cells without that transporter, the cells became lazy, survived poorly, and failed to prep T cells for battle. T cells grown with these creatine-starved dendritic cells multiplied less and produced fewer signaling molecules - basically, the immune system showed up to the fight with a limp handshake.

Conversely, daily creatine injections in mice with melanoma slowed tumor growth and boosted the number and activity of tumor-infiltrating dendritic cells. Those treated cells also released more chemical signals to recruit additional immune cells. Metabolomics analyses revealed that creatine increased intracellular ATP levels in dendritic cells - ATP being the cellular energy currency that powers everything, like a rechargeable battery for the immune system's scouts. The researchers say this helps dendritic cells maintain their inflammatory signaling pathways even while competing with greedy tumor cells for nutrients.

The team also tested creatine on human immune cells in the lab and found it enhanced activation of monocyte-derived dendritic cells - the kind used in dendritic cell cancer vaccines - and improved their ability to stimulate human T cells against a cancer target. This suggests creatine could be used to beef up vaccines before they're even injected. 'The potential we see here is that creatine could be used in two complementary ways: as a supplement to enhance the immune response of patients already receiving immunotherapy, and as a tool to improve the quality of dendritic cell-based vaccines before they're administered,' said James Elsten-Brown, a co-first author.

Before you rush to stock up on creatine gummies, the researchers caution that this work is still in the early stages - mice and lab cells, not actual cancer patients. Creatine monohydrate is generally considered safe at recommended doses, but anyone undergoing cancer treatment should consult their doctor before adding any supplement. The next step is clinical trials to see if creatine can actually improve outcomes for people on immunotherapy. The study was funded by various UCLA grants and fellowships, and the potential therapeutic strategy is the subject of a patent application by UCLA. So, for now, creatine remains a gym staple with a promising side hustle in immunology - but don't cancel your oncologist just yet.